Klin Farmakol Farm. 2006;20(2):90-96

Pharmacotherapy of stable chronic obstructive pulmonary disease

MUDr. Viktor Kašák1,2
1 Česká iniciativa pro astma (ČIPA o. p. s.), Praha
2 Oddělení respiračních nemocí, LERYMED spol. s r. o., Praha

A contemporary review of pharmacotherapy of stable chronic obstructive pulmonary disease (COPD) in the Czech Republic is presented in this article.

Keywords: chronic obstructive pulmonary disease (COPD), pharmacotherapy of stable COPD

Published: September 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kašák V. Pharmacotherapy of stable chronic obstructive pulmonary disease. Klin Farmakol Farm. 2006;20(2):90-96.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Halbert RJ, Isonaka S, Kabal A. Interpriting COPD prevalence estimates: what is true burden of disease? Chest 2003; 123: 1684-1692. Go to original source... Go to PubMed...
    2. World Health Report 2002. Geneva: World Health Organisation, 2002. www.who.int/whr/2002/en.
    3. Vondra V. Malý M, Švandová E, Rozborilová E. Úmrtnost na chronickou obstrukční plicní nemoc v ČR a SR v letech 1999-2003. Medicína po promoci 2005; 6: 80-88.
    4. Global Initiative for Chronic Obstructive Lung Diasease. NHLBI/WHO, Publication No. 2701, 2001: 100 s.
    5. Celli BR, MacNee W, and committee members. Standards for diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. Go to original source... Go to PubMed...
    6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated July 2005. www.goldcopd.com
    7. Vestbo J. What is an exacerbation of COPD? Eur Respir Rev 2004; 13, 88: 6-13.
    8. Partridge MR. Living with COPD: patients' perspective. Eur Respir Rev 2004; 13, 88: 1-5.
    9. Wounters EF. Economic analysis of the confronting COPD sorbet: an overview of results. Respir Med 2003; 97: (Suppl. C): S3-S14. Go to original source... Go to PubMed...
    10. Miravittles M, Murio C, Guerrero T, Gilbert R, DAFINE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1445. Go to original source... Go to PubMed...
    11. Anderson F, Borg S, Jansson SA, et al. The cost of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-708. Go to original source... Go to PubMed...
    12. Tashkin DP, Cooper CB. The role of long-acting bronchodilatators in the management of stable COPD. Chest 2004; 125: 249-259. Go to original source... Go to PubMed...
    13. Pauk N. Současné postavení dlouhodobě působících bronchodilatancií v léčbě stabilní chronické obstrukční plicní nemoci. Farmakoterapie 2005; 1: 379-384.
    14. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Inhaled tiotropium for stable chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2005; Issue 2, Art. No.: CD002876. pub2. Go to original source...
    15. Kašák V. Tiotropium. Remedia 2005; 15: 205-211.
    16. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology & Therapeutics 2005; 18: 75-81. Go to original source... Go to PubMed...
    17. van Noor J, Aumann J, Jansens E, et al. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD. Respir Crit Care Med 2003; A320.
    18. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintance therapy in patients with COPD. Am Respir Med 2004; 3 (4): 1-23. Go to original source...
    19. ZuWallack AR, ZuWallack RL. Tiotropium bromide, a new once-daily inhaled anticholinergic bronchodilatator for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2004; 5: 1827-1835. Go to original source... Go to PubMed...
    20. Barnes PJ. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363: 731-733. Go to original source... Go to PubMed...
    21. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patiens with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-780. Go to original source... Go to PubMed...
    22. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303. Go to original source... Go to PubMed...
    23. Jones PW, Willits LR, Burge PS, Calverley PM and the Inhaled Steroids in Obstructive Lung Disease In Europe Study Investigators. Disease Severity and the effect of fluticasone propionate on chronic obstructive pulmonary diasease exacerbations. Eur Respir J 2003; 21: 68-73. Go to original source... Go to PubMed...
    24. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584. Go to original source... Go to PubMed...
    25. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819-825. Go to original source... Go to PubMed...
    26. Soriano JB, Kiri V, Pride NB, et al. Inhaled corticosteroids with/without long acting beta agonists reduce risk of re-hospitalisation and death in COPD patients. Am J Respir Med 2003; 2: 67-74. Go to original source... Go to PubMed...
    27. Matthews JG, Ito K, Barnes PJ, Addock M. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004; 113: 1100-1108. Go to original source... Go to PubMed...
    28. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting ?2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191. Go to original source... Go to PubMed...
    29. Kašák V. Farmakologická prevence exacerbací chronické obstrukční plicní nemoci fixní kombinací budesonid/formoterol. Stud Pneumol Phtiseol 2005; 65: 208-213.
    30. Calverley PM, Pauwels R, Vesbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456. Go to original source... Go to PubMed...
    31. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81. Go to original source... Go to PubMed...
    32. Calverley PM, Boonsawat W, Czeke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919. Go to original source... Go to PubMed...
    33. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 2005; 11: 129-134. Go to original source... Go to PubMed...
    34. Dahl M, Hersh CP, Ly NP, et al. The protease inhibitor PIS Allele and COPD: a meta-analysis. Eur Respir J 2005; 26: 67-76. Go to original source... Go to PubMed...
    35. Chlumský J, Vašáková M. Standard pro diagnostiku a léčbu pacientů s CHOPN s prokázanou deficiencí alfa-1 antitrypsinu (AAT). 2005; www.pneumologie.cz
    36. NICE Guideline - COPD 2004. Www.nice.org.uk/pdf/CG012_niceguideline.pdf
    37. Kolek V. Mukolytika - léky nejen proti kašli. Med. Pro Prax 2001; 2: 62-67.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.